<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878798</url>
  </required_header>
  <id_info>
    <org_study_id>URNN001</org_study_id>
    <nct_id>NCT02878798</nct_id>
  </id_info>
  <brief_title>Topiramate for Cryptogenic Sensory Peripheral Neuropathy</brief_title>
  <acronym>TopCSPN</acronym>
  <official_title>Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroNEXT Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate
      as a potential disease altering therapy for cryptogenic sensory peripheral neuropathy (CSPN).
      Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria) who do
      not have an alternative cause for neuropathy will be potentially eligible. The co primary
      outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy (NQOL-DN)
      Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The treatment phase
      will last 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraepidermal nerve fiber density (IENFD)</measure>
    <time_frame>Baseline 9, 18, and 24 months</time_frame>
    <description>Difference in IENFD change between treatment groups over 24 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norfolk Quality of Life - Diabetic Neuropathy</measure>
    <time_frame>Baseline, 9, 18, and 24 months</time_frame>
    <description>Difference in NQOL between treatment groups over 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nerve conduction studies</measure>
    <time_frame>Baseline, 9, 18, and 24 months</time_frame>
    <description>association of NCS outcomes to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utah Early Neuropathy Scale</measure>
    <time_frame>Baseline, 4, 8, 12, 16, 20, 24 months</time_frame>
    <description>association of UENS to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and Go</measure>
    <time_frame>Baseline, 9, 18 and 24 months</time_frame>
    <description>association of TUG change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>Baseline, 9, 18, and 24 months</time_frame>
    <description>association of 6MW change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy Total Symptom Score - 6</measure>
    <time_frame>Baseline, 4, 8, 12, 16, 20, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief pain inventory</measure>
    <time_frame>Baseline, 4, 8, 12, 16, 20, 24 months</time_frame>
    <description>association of BPI change to NQOL and IENFD changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Cryptogenic Sensory Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral topiramate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>Oral topiramate at a target dose of 50mg twice daily.</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>overencapsulated placebo of identical color, shape and packaging to topiramate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age 18-75

          2. Diagnosis of confirmed cryptogenic symptomatic distal symmetric peripheral
             polyneuropathy based on the Toronto consensus criteria for confirmed neuropathy
             (signs, symptoms, and an abnormality of NCS or IENFD)

          3. Evidence of symptomatic neuropathy based on a screening visit NQOL- DN score of &gt;27
             (the score among 379 American and European diabetic patients with mild neuropathy).

          4. Metabolic syndrome based on the ATPIII criteria, with a BMI ≥ 25 kg/m2 Specific
             criteria require 3 of the following 5 to be present at the screening visit.

          5. No current or prior history of therapy with topiramate.

          6. If female of child-bearing potential (i.e., not surgically sterile or post-menopausal
             defined as age &gt; 51 years without menses for ≥ 2 years), negative serum pregnancy test
             at screening and negative urine pregnancy test at baseline visit.

          7. Women of child-bearing potential or men with sexual partners of childbearing potential
             be willing to use an acceptable method of birth control for the duration of the study
             and for 12 weeks following completion of study drug therapy. Acceptable methods of
             birth control include abstinence, oral contraceptives, the contraceptive patch,
             intra-uterine device, the contraceptive ring, and or barrier contraception such as
             condoms with spermicide.

        Exclusion Criteria

          1. Any identified alternative cause for peripheral neuropathy (including but not limited
             to rheumatological disorders, Hepatitis B or C, Breast Cancer treated with neurotoxic
             chemotherapy within the past 15 years). All potential subjects will have screening
             neuropathy labs including assessment for diabetes (Hemoglobin A1c, oral glucose
             tolerance test), vitamin B12 level, and immunofixation.

          2. Diagnosis of diabetes by history, or screening laboratory results including: HgA1c ≥
             6.5%, fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), or 2-hour oral glucose
             tolerance ≥ 200 mg/dL (11.1 mmol/L). Borderline screening labs can be repeated within
             two weeks with PPI approval.

          3. History of nephrolithiasis or use of ongoing preventative treatment.

          4. Family history of a non-diabetic neuropathy in a first-degree relative.

          5. Severe neuropathy: Utah Early Neuropathy Score &gt; 24 at screening

          6. Active foot ulceration or a history of a nontraumatic foot amputation.

          7. ECG with QTc more than 450 ms in men, or 470 ms in women.

          8. Current or planned therapeutic anticoagulation including coumadin or oral factor X or
             thrombin inhibitor therapy (anti-platelet agents are permissible).

          9. Chronic corticosteroid use excluding topical treatment.

         10. Use of a carbonic anhydrase inhibitor (such as acetazolamide) due to risk of
             nephrolithiasis.

         11. Planned bariatric surgery

         12. Use of other weight loss medications.

         13. Use of neuropathic pain agents beyond first line agents (permissible first line agents
             include gabapentin, pregabalin, tricyclic antidepressants, duloxetine, venlafaxine,
             tramadol less than 200 mg daily, or topical lidocaine).

         14. Use of scheduled opiates, or as needed opiate medications more than three times
             weekly.

         15. Use of topical capsaicin products within 16 weeks of screening or at any time on
             study.

         16. Medication change for neuropathy symptoms during the 8 weeks prior to screening; or
             anticipated change for the duration of study participation.

         17. Current use of an intrathecal pain pump or spinal cord stimulator.

         18. Screening laboratory values above normal limits as follows: AST/ALT ≥1.5 times upper
             limit normal, creatinine ≥ 2.0 mg/dl.

         19. Severe edema, dermatologic or lower extremity condition that would increase risk of
             skin biopsy.

         20. Major depression, bipolar affective disorder, or other mental health disorders that
             are sufficiently severe to increase adverse event risk or impact neuropathy assessment
             in the opinion of the responsible site principal investigator.

         21. Current suicidal ideation within one year prior to the baseline visit as evidenced by
             answering &quot;yes&quot; to Questions 4 or 5 on the suicidal ideation portion of the
             Columbia-Suicide Severity Rating Scale (C-SSRS).

         22. Ataxia sufficiently severe to represent an unacceptable fall risk in the opinion of
             the site principal investigator.

         23. A serious medical condition expected to dramatically shorten life span or prevent
             participation.

         24. Any clinically significant condition or illness, which, in the opinion of the
             investigator, would pose a risk to the subject or might confound the study including
             metabolic acidosis, bone marrow suppression, blood dyscrasias, bleeding disorder, or
             closed angle glaucoma.

         25. History of alcohol or drug abuse.

         26. History of malignancy within five years prior to study enrollment, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.

         27. A history of epilepsy.

         28. An inability to understand or cooperate with the procedures of the study.

         29. Pregnant, or intending to become pregnant, or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gordon Smith, MD</last_name>
    <phone>801-585-9516</phone>
    <email>gordon.smith@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Benge</last_name>
      <phone>205-975-0445</phone>
      <email>melaniebenge@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Eroboghene Ubogu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Blume</last_name>
      <phone>303-724-6386</phone>
      <email>brianna.blume@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Dianna Quan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Levy</last_name>
      <phone>305-243-6724</phone>
      <email>wel20@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mario Saporta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Ward</last_name>
      <phone>312-503-2128</phone>
      <email>tina.ward@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela Menichella, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Parks</last_name>
      <phone>913-945-9938</phone>
      <email>cparks@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Mamatha Pasnoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter James</last_name>
      <phone>617-643-4218</phone>
      <email>pfjames@partners.org</email>
    </contact>
    <investigator>
      <last_name>Reza Seyedsadjadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengesha Teshome</last_name>
      <phone>314-747-8420</phone>
      <email>teshomem@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Glenn Lopate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Patch</last_name>
      <phone>718-920-6690</phone>
      <email>donna.patch@einstein.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Milstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arruem Kim</last_name>
      <phone>212-305-6036</phone>
      <email>ak3905@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Brannagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Sowden</last_name>
      <phone>585-275-1267</phone>
      <email>janet_sowden@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>David Herrmann, MBBCh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bartlett</last_name>
      <phone>614-366-9005</phone>
      <email>amy.bartlett@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Amro Stino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Adkins</last_name>
      <phone>615-936-1646</phone>
      <email>karen.adkins@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Peltier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariam Andersen</last_name>
      <phone>214-648-6329</phone>
      <email>mariam.andersen@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Doudova</last_name>
      <phone>801-581-3818</phone>
      <email>mariana.doudova@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Rob Singleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolina Caselllini</last_name>
      <phone>757-446-7976</phone>
      <email>casellcm@evms.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Vinik, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>April 8, 2018</last_update_submitted>
  <last_update_submitted_qc>April 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Gordon Smith</investigator_full_name>
    <investigator_title>Professor and Vice Chair of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

